 |
PDBsum entry 3wcf
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Squalene synthase as a target for chagas disease therapeutics.
|
 |
|
Authors
|
 |
N.Shang,
Q.Li,
T.P.Ko,
H.C.Chan,
J.Li,
Y.Zheng,
C.H.Huang,
F.Ren,
C.C.Chen,
Z.Zhu,
M.Galizzi,
Z.H.Li,
C.A.Rodrigues-Poveda,
D.Gonzalez-Pacanowska,
P.Veiga-Santos,
T.M.De carvalho,
W.De souza,
J.A.Urbina,
A.H.Wang,
R.Docampo,
K.Li,
Y.L.Liu,
E.Oldfield,
R.T.Guo.
|
 |
|
Ref.
|
 |
Plos Pathog, 2014,
10,
e1004114.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Trypanosomatid parasites are the causative agents of many neglected tropical
diseases and there is currently considerable interest in targeting endogenous
sterol biosynthesis in these organisms as a route to the development of novel
anti-infective drugs. Here, we report the first x-ray crystallographic
structures of the enzyme squalene synthase (SQS) from a trypanosomatid parasite,
Trypanosoma cruzi, the causative agent of Chagas disease. We obtained five
structures of T. cruzi SQS and eight structures of human SQS with four classes
of inhibitors: the substrate-analog S-thiolo-farnesyl diphosphate, the
quinuclidines E5700 and ER119884, several lipophilic bisphosphonates, and the
thiocyanate WC-9, with the structures of the two very potent quinuclidines
suggesting strategies for selective inhibitor development. We also show that the
lipophilic bisphosphonates have low nM activity against T. cruzi and inhibit
endogenous sterol biosynthesis and that E5700 acts synergistically with the
azole drug, posaconazole. The determination of the structures of trypanosomatid
and human SQS enzymes with a diverse set of inhibitors active in cells provides
insights into SQS inhibition, of interest in the context of the development of
drugs against Chagas disease.
|
 |
|
|
|
|
 |